CCL5 has been reported to trigger invasion by increasing the release of matrix metalloproteinases 2 and 9 in prostate cancer and cancer cell motility and invasion by being secreted by mesenchymal stem cells in the TME in breast cancer [26,27]. Here, CCL5 is linked to breast carcinoma.